Spots Global Cancer Trial Database for ganitumab
Every month we try and update this database with for ganitumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | NCT03041701 | Rhabdomyosarcom... Rhabdomyosarcom... Rhabdomyosarcom... | Dasatinib Dasatinib Ganitumab | 2 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer | NCT01473303 | Pancreatic Canc... | ganitumab fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin placebo questionnaire a... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | NCT03041701 | Rhabdomyosarcom... Rhabdomyosarcom... Rhabdomyosarcom... | Dasatinib Dasatinib Ganitumab | 2 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | NCT02306161 | Metastatic Ewin... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Peri... Peripheral Prim... | Cyclophosphamid... Doxorubicin Doxorubicin Hyd... Etoposide Etoposide Phosp... External Beam R... Ganitumab Ifosfamide Stereotactic Ra... Therapeutic Sur... Vincristine Vincristine Sul... | - 50 Years | National Cancer Institute (NCI) | |
| Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) | NCT00788957 | Colon Cancer Colorectal Canc... Gastrointestina... Metastatic Colo... Rectal Cancer | Panitumumab Ganitumab Rilotumumab Placebo | 18 Years - | Amgen | |
| Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas | NCT01298401 | Pancreatic Canc... | ganitumab capecitabine gemcitabine hyd... 3-dimensional c... | 18 Years - | Radiation Therapy Oncology Group | |
| Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas | NCT01298401 | Pancreatic Canc... | ganitumab capecitabine gemcitabine hyd... 3-dimensional c... | 18 Years - | Radiation Therapy Oncology Group | |
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | NCT04199026 | Metastatic Sarc... Recurrent Sarco... Resectable Sarc... | Doxorubicin Doxorubicin Hyd... Drug Delivery M... Everolimus Ganitumab Ifosfamide Irinotecan Pazopanib Polyethylene Gl... Temozolomide Temsirolimus Therapeutic Con... Vincristine | 10 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer | NCT01473303 | Pancreatic Canc... | ganitumab fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin placebo questionnaire a... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab | NCT00891930 | Metastatic Colo... | Panitumumab Ganitumab Irinotecan | 18 Years - | Amgen | |
| Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | NCT02306161 | Metastatic Ewin... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Peri... Peripheral Prim... | Cyclophosphamid... Doxorubicin Doxorubicin Hyd... Etoposide Etoposide Phosp... External Beam R... Ganitumab Ifosfamide Stereotactic Ra... Therapeutic Sur... Vincristine Vincristine Sul... | - 50 Years | National Cancer Institute (NCI) | |
| Palbociclib + Ganitumab In Ewing Sarcoma | NCT04129151 | Ewing Sarcoma Ewing's Sarcoma... | Palbociclib Ganitumab | 12 Years - 50 Years | Dana-Farber Cancer Institute | |
| A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | NCT01562899 | Metastatic Panc... BRAF Mutated Me... | MEK162 AMG 479 | 18 Years - | Pfizer | |
| Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas | NCT01298401 | Pancreatic Canc... | ganitumab capecitabine gemcitabine hyd... 3-dimensional c... | 18 Years - | Radiation Therapy Oncology Group | |
| Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | NCT03041701 | Rhabdomyosarcom... Rhabdomyosarcom... Rhabdomyosarcom... | Dasatinib Dasatinib Ganitumab | 2 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
